Diabetes & Endocrinology
Latest news
532 articles · 20 / page
SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia
Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where trad
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patien
Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont
Smart Speakers for Diabetes: Bridging the Gap Between Mental Wellbeing and Glycemic Control in Older Adults
The IVAM-ED trial demonstrates that interactive virtual assistants significantly reduce mental distress and improve HbA1c levels in older adults with type 2 diabetes, highlighting a scalable solution for geriatric chronic disease management
Beta-Cell Function, Not Glucagon, Predicts Glycemic Success: A Critical Analysis of the GRADE Study
A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting
High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations
A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resis
Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management
The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ
Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers
A randomized controlled trial investigates the 6-month effects of intermittent fasting on overweight adults, revealing significant improvements in lipid profiles and body composition despite neutral effects on blood pressure and glucose met
Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes
A randomized controlled trial demonstrates that a 20g whey protein pre-load 30 minutes before breakfast significantly reduces postprandial glucose excursions and glycemic variability in women with gestational diabetes throughout the third t
Preemptive Magnesium Sulfate Infusion Significantly Stabilizes Hemodynamics During Pheochromocytoma Resection
A randomized, double-blind trial confirms that preemptive magnesium sulfate reduces intraoperative hemodynamic instability by nearly 50% in patients undergoing pheochromocytoma and paraganglioma resection, providing a safe and effective adj
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of t
Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients
A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and
Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics
This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.
Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial
A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differ
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase
Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial
A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering
Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial
The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement
Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile and m
Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial
The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin
Browse by specialty
Open language-specific specialty feeds and department pages.